The World Health Organization (WHO) has announced the end of the public health emergency for Covid-19, marking the end of a declaration that had been in effect for more than three years.
During a meeting on Friday, WHO officials pointed toward decreasing trends in infections, hospitalisations, and deaths stemming from Covid-19 in the international community. As a result, the organisation determined that countries should treat the virus as an endemic threat rather than an acute emergency.
The WHO Director-General concurred with the advice of the committee, officially ending what had been deemed a public health emergency of international concern (PHEIC) since March 2020. In the US, the public health emergency for Covid-19 is set to end on May 11.
Covid-19 clinical trial activity remains high
As the world shifts toward viewing Covid-19 as an endemic virus, the pharma industry is still pouring resources into developing new treatments. There are more than 1,000 ongoing drug and vaccine trials targeting Covid-19, according to GlobalData’s Clinical Trials Database.
Though most ongoing Covid-19 trials have institutions like academic research centers as sponsors, industry sponsors a sizeable share of studies. Meanwhile, studies aimed at Covid-19 continue to dominate the infectious disease drug development landscape.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe WHO’s new policy reflects changing expert opinions on how to handle Covid-19 as the virus and its community impact continue to evolve. Earlier this year, the organisation recommended bivalent vaccines, offering different vaccine and booster schedules depending on an individual’s risk.